XARELTO®: Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients◇

Once-daily risk reduction from VTE events in acutely ill medical patients from inpatient to outpatient◇

VTE PROPHYLAXIS DOSING Once-daily oral VTE risk reduction in acutely ill medical patients

VTE PROPHYLAXIS EFFICACY VTE risk reduction at Day 10 and Day 35 vs standard of care

VTE PROPHYLAXIS SAFETY Bleeding events in MAGELLAN subgroup at Day 35

VTE PROPHYLAXIS CLINICAL TRIALS The MAGELLAN trial studied acutely ill medical patients at risk for a VTE1

VTE PLATFORM 6 indications to treat and help protect from a VTE—both inpatient and outpatient*1-7

JANSSEN CAREPATH XARELTO® Savings Program

FORMULARY FINDER Coverage for your patients

Medically Ill Resources

DOSING ACROSS INDICATIONS Condition-specific dosing for XARELTO®

MAGELLAN REPRINT Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

VTE PLATFORM 6 indications to treat and help protect from a VTE—both inpatient and outpatient*1-7

View all resources

◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bl

*The decision regarding initiation setting should be based on the prescriber's clinical judgment.

VTE = venous thromboembolism.

References: 1. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523. 2. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. 3. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 4. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. 5. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775. 6. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39. 7. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.